There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
REGULATORY
Japan Approves Pfizer COVID-19 Vaccine for Booster Use
Japan’s health ministry on November 11 granted special emergency approval to Pfizer’s COVID-19 vaccine Comirnaty for its use as a booster shot, or the third dose of coronavirus inoculation, covering individuals aged 18 and older. The approval of Comirnaty’s booster…
To read the full story
Related Article
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
- Shorter Booster Interval for All Citizens Difficult: Health Minister
December 8, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
- Pfizer’s COVID-19 Booster Now in Line for Approval for Age 18-Plus
November 11, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
- Booster Shots to Start with Pfizer Vaccine: MHLW
November 2, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
- Govt to Deliver 4.12 Million Comirnaty Doses for COVID-19 Boosters: Minister
October 19, 2021
- Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
- MHLW Eyes Booster Shots for Healthcare Workers from December
September 24, 2021
- Japan Needs Setups to Execute Booster Shots by Year-End: Minister
September 22, 2021
- Japan to Offer COVID-19 Booster Shots, Targets to Be Discussed Later
September 21, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- Japan in Talks with Pfizer over 120 Billion Booster Shots for 2022
August 23, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
REGULATORY
- Generic Makers Flock to Samsca’s Heart Failure Market after Patent Invalidated; Gx Listing Expected in December
August 16, 2022
- Authorized Generics Approved for Nexium, Samsca, Lipitor, Careram
August 16, 2022
- First Generics for 5 APIs Approved towards December Listing, with 8 Firms for Nexium
August 16, 2022
- MHLW Leaks Personal Info on Intractable Disease Patients
August 16, 2022
- Lilly’s GIP/GLP-1 Receptor Agonist Up for PAFSC Review on August 25
August 15, 2022
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…